Abstract: The present invention relates to a compound of formula (I) which is useful for inhibiting neoplasms where the resistance is conferred in part or in total by MRP1.
Type:
Grant
Filed:
September 13, 2000
Date of Patent:
April 24, 2001
Assignee:
Eli Lilly and Company
Inventors:
Joseph Michael Gruber, Sean P Hollinshead, Bryan H Norman, Joseph W Wilson